Patrick Bryant
@patrickbryant1.bsky.social
Assistant Professor at Stockholm University.
Dedicated Scientist.
Dedicated Scientist.
The future of drug design is in AI. RareFoldGPCR: Agonist Design Beyond Natural Amino Acids.
Paper: www.biorxiv.org/content/10.1...
Code: github.com/patrickbryan...
Paper: www.biorxiv.org/content/10.1...
Code: github.com/patrickbryan...
October 3, 2025 at 3:09 PM
The future of drug design is in AI. RareFoldGPCR: Agonist Design Beyond Natural Amino Acids.
Paper: www.biorxiv.org/content/10.1...
Code: github.com/patrickbryan...
Paper: www.biorxiv.org/content/10.1...
Code: github.com/patrickbryan...
Update: RareFold 🧬
Our AI framework for protein design with 29 noncanonical AAs now shows designed binders (linear + cyclic) are non-immunogenic in patient-derived assays — paving the way for safe next-gen peptide therapeutics.
👉https://www.biorxiv.org/content/10.1101/2025.05.19.654846v2
Our AI framework for protein design with 29 noncanonical AAs now shows designed binders (linear + cyclic) are non-immunogenic in patient-derived assays — paving the way for safe next-gen peptide therapeutics.
👉https://www.biorxiv.org/content/10.1101/2025.05.19.654846v2
RareFold: Structure prediction and design of proteins with noncanonical amino acids
Protein structure prediction and design have traditionally been limited to the 20 canonicalamino acids. Expanding this space to include noncanonical amino acids (NCAAs) offers newopportunities for pro...
www.biorxiv.org
September 9, 2025 at 7:36 PM
Update: RareFold 🧬
Our AI framework for protein design with 29 noncanonical AAs now shows designed binders (linear + cyclic) are non-immunogenic in patient-derived assays — paving the way for safe next-gen peptide therapeutics.
👉https://www.biorxiv.org/content/10.1101/2025.05.19.654846v2
Our AI framework for protein design with 29 noncanonical AAs now shows designed binders (linear + cyclic) are non-immunogenic in patient-derived assays — paving the way for safe next-gen peptide therapeutics.
👉https://www.biorxiv.org/content/10.1101/2025.05.19.654846v2
Our study where we develop EvoBind2: Design of linear and cyclic peptide binders from protein sequence information is now published! www.nature.com/articles/s42...
July 22, 2025 at 11:23 AM
Our study where we develop EvoBind2: Design of linear and cyclic peptide binders from protein sequence information is now published! www.nature.com/articles/s42...
Cool! Congrats @proteinator.bsky.social 🎉
1/6 One of the key features of functional proteins is their inherent structural flexibility. In our recent work at #ICML, we introduce flexibility to protein structure design! More in a thread below.
Code / Tutorial: github.com/graeter-grou...
Poster: W-109, Thu 17 Jul 11 a.m. PDT — 1:30 p.m. PDT
Code / Tutorial: github.com/graeter-grou...
Poster: W-109, Thu 17 Jul 11 a.m. PDT — 1:30 p.m. PDT
July 17, 2025 at 5:49 AM
Cool! Congrats @proteinator.bsky.social 🎉
Now published: our study on human-pathogen protein-protein interactions! We identify 30 interactions with an expected TM-score ≥0.9, tripling the structural coverage in these networks. One novel interaction was validated with mass spectrometry. journals.plos.org/ploscompbiol...
July 6, 2025 at 8:02 AM
Now published: our study on human-pathogen protein-protein interactions! We identify 30 interactions with an expected TM-score ≥0.9, tripling the structural coverage in these networks. One novel interaction was validated with mass spectrometry. journals.plos.org/ploscompbiol...
Our latest work is out: we designed dual GLP1R/GCGR agonists—cyclic peptides that activate both metabolic receptors, entirely from sequence alone.
This has never been done before. www.biorxiv.org/content/10.1...
This has never been done before. www.biorxiv.org/content/10.1...
June 9, 2025 at 7:00 AM
Our latest work is out: we designed dual GLP1R/GCGR agonists—cyclic peptides that activate both metabolic receptors, entirely from sequence alone.
This has never been done before. www.biorxiv.org/content/10.1...
This has never been done before. www.biorxiv.org/content/10.1...
You can also design in Colab now: colab.research.google.com/github/patri...
May 27, 2025 at 12:40 PM
You can also design in Colab now: colab.research.google.com/github/patri...
Happy to release our breakthrough AI-model: RareFold, which predicts and designs proteins with noncanonical AAs. With EvoBindRare, we designed linear & cyclic peptide binders with high affinity & novel binding modes, wet lab validated.
📄 biorxiv.org/content/10.1...
💻 github.com/patrickbryan...
📄 biorxiv.org/content/10.1...
💻 github.com/patrickbryan...
May 25, 2025 at 2:11 PM
Happy to release our breakthrough AI-model: RareFold, which predicts and designs proteins with noncanonical AAs. With EvoBindRare, we designed linear & cyclic peptide binders with high affinity & novel binding modes, wet lab validated.
📄 biorxiv.org/content/10.1...
💻 github.com/patrickbryan...
📄 biorxiv.org/content/10.1...
💻 github.com/patrickbryan...